{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:51:43Z","timestamp":1791669103847,"version":"4.3.4"},"reference-count":11,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":266,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Limited evidence exists evaluating the impact of gabapentin in conjunction with benzodiazepines for the management of alcohol withdrawal. A review of outcomes associated with combination gabapentin and benzodiazepine therapy may illuminate new therapeutic uses in clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study evaluated the impact of gabapentin on as-needed use of benzodiazepines in inpatients being treated for acute alcohol withdrawal. The treatment cohort consisted of patients prescribed gabapentin while on a symptom-triggered alcohol withdrawal protocol. The control cohort consisted of patients on symptom-triggered alcohol withdrawal protocol without concurrent gabapentin use. Secondary objectives included length of hospital stay, duration on alcohol withdrawal protocol, frequency of complicated withdrawal, and use of additionally prescribed as-needed or scheduled benzodiazepines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The gabapentin cohort was on the alcohol withdrawal protocol for a similar duration, compared with the control cohort (median of 4 [interquartile range: 2,6] days vs 3 [2,4] days, P\u2009=\u2009.09, respectively). Similarly, the gabapentin cohort required a median of 1 [1,2] benzodiazepine dose for alcohol withdrawal symptoms compared with a median of 1 [1,2] dose in the control cohort, P\u2009=\u2009.89. No significant difference was found between cohorts for as-needed and scheduled benzodiazepine use. Length of stay in hospital was similar between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>These results suggest that gabapentin use, in conjunction with benzodiazepines, impacts neither the time on alcohol withdrawal protocol or the number of benzodiazepine doses required for withdrawal. Larger, prospective studies are needed to detect if gabapentin alters benzodiazepine usage and to better elucidate gabapentin's role in acute alcohol withdrawal.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T22:39:54Z","timestamp":1546641594000},"page":"1-5","source":"Crossref","is-referenced-by-count":12,"title":["Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility"],"prefix":"10.9740","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8134-2082","authenticated-orcid":false,"given":"Taylor A.","family":"Nichols","sequence":"first","affiliation":[{"name":"(Corresponding author) Clinical Pharmacy Specialist \u2013 Mental Health, Phoenix Veteran's Affairs Health Care System, Phoenix, Arizona, taylor.nichols@va.gov"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4221-0252","authenticated-orcid":false,"given":"Sophie","family":"Robert","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Specialist \u2013 Psychiatry, Medical University of South Carolina, Charleston, South Carolina; Research Assistant Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina; Adjunct Assistant Professor, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7273-4589","authenticated-orcid":false,"given":"David J.","family":"Taber","sequence":"additional","affiliation":[{"name":"Associate Professor, Medical University of South Carolina Division of Transplant Surgery, Charleston, South Carolina; Clinical Pharmacy Specialist \u2013 Transplant and Research, Ralph H. Johnson Veteran's Affairs Medical Center, Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-5301","authenticated-orcid":false,"given":"Jeffrey","family":"Cluver","sequence":"additional","affiliation":[{"name":"Deputy Chair, Vice Chair for Education and Training, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"key":"2022042017071531600_i2168-9709-9-1-1-b01","article-title":"LABEL: GABAPENTIN - gabapentin capsule","author":"DailyMed [Internet]","year":"2013"},{"issue":"11","key":"2022042017071531600_i2168-9709-9-1-1-b02","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","article-title":"Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Furieri","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"2022042017071531600_i2168-9709-9-1-1-b03","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2022042017071531600_i2168-9709-9-1-1-b04","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"5","key":"2022042017071531600_i2168-9709-9-1-1-b05","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/01.jcp.0000088905.24613.ad","article-title":"Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-center trial","volume":"23","author":"Bonnet","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"2022042017071531600_i2168-9709-9-1-1-b06","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/10550490500419110","article-title":"A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal","volume":"15","author":"Mariani","year":"2006","journal-title":"Am J Addict"},{"issue":"9","key":"2022042017071531600_i2168-9709-9-1-1-b07","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/j.1530-0277.2009.00986.x","article-title":"A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal","volume":"33","author":"Myrick","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"issue":"7-8","key":"2022042017071531600_i2168-9709-9-1-1-b08","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1345\/aph.1R751","article-title":"Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment","volume":"47","author":"Stock","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"11","key":"2022042017071531600_i2168-9709-9-1-1-b09","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Addiction"},{"issue":"4","key":"2022042017071531600_i2168-9709-9-1-1-b10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"issue":"9","key":"2022042017071531600_i2168-9709-9-1-1-b11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/pds.4230","article-title":"Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings","volume":"26","author":"Buttram","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/1\/1\/3047093\/mhc_2019_01_001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/9\/1\/1\/3047093\/mhc_2019_01_001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:22:48Z","timestamp":1731687768000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/9\/1\/article-p1.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2019.01.001","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,1]]}}}